Traders Purchase Large Volume of Call Options on AbbVie (NYSE:ABBV)

AbbVie Inc. (NYSE:ABBV) was the recipient of some unusual options trading on Wednesday. Investors bought 86,296 call options on the company. This is an increase of approximately 445% compared to the average daily volume of 15,836 call options.

AbbVie Stock Up 3.4%

Shares of NYSE ABBV traded up $9.22 during trading hours on Wednesday, reaching $283.58. 5,585,527 shares of the stock traded hands, compared to its average volume of 6,410,414. AbbVie has a 52-week low of $190.75 and a 52-week high of $285.40. The company has a market capitalization of $501.03 billion, a P/E ratio of 80.11, a price-to-earnings-growth ratio of 1.28 and a beta of 0.24. The company’s 50-day simple moving average is $260.41 and its two-hundred day simple moving average is $237.87.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts forecast that AbbVie will post 13.95 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a $1.73 dividend. The ex-dividend date is Thursday, October 15th. This represents a $6.92 annualized dividend and a yield of 2.4%. AbbVie’s payout ratio is presently 195.48%.

Analysts Set New Price Targets

ABBV has been the subject of a number of recent research reports. JPMorgan Chase & Co. boosted their price objective on AbbVie from $285.00 to $300.00 and gave the stock an “overweight” rating in a report on Thursday, October 8th. Citigroup raised their target price on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research report on Wednesday, July 15th. Guggenheim reiterated a “buy” rating and issued a $288.00 price objective on shares of AbbVie in a research note on Friday, October 9th. Sanford C. Bernstein reiterated a “market perform” rating and issued a $225.00 target price (up from $203.00) on shares of AbbVie in a research note on Tuesday, June 23rd. Finally, Morgan Stanley boosted their price objective on AbbVie from $296.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $277.18.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New Phase 3 AFFIRM data showed that a subcutaneous version of SKYRIZI produced meaningful clinical and endoscopic responses in adults with moderately to severely active Crohn’s disease, with a safety profile consistent with the established treatment. The results could support regulatory review of a more convenient induction option and expand SKYRIZI’s commercial opportunity. AbbVie’s Crohn’s Disease Drug SKYRIZI Shows More Positive Results
• Positive Sentiment: Additional SKYRIZI and RINVOQ inflammatory bowel disease updates, along with expectations for strong growth from Rinvoq, Skyrizi and Vraylar, have improved confidence in AbbVie’s post-Humira revenue drivers. RBC also expects the company to deliver a third-quarter top-line beat. AbbVie Poised for Q3 Top-Line Beat
• Positive Sentiment: Erste Group Bank raised its FY2027 EPS forecast for AbbVie to $16.34 from $16.19 and maintained a Buy rating. Several analysts have also remained constructive, including RBC, which reaffirmed an Outperform rating. AbbVie analyst estimate update
• Neutral Sentiment: Analysts and investors remain divided on valuation. Comparisons with Sanofi favor Sanofi because of its upgraded outlook, Dupixent growth and lower valuation, while other analyses argue AbbVie’s recent pipeline wins could make the shares undervalued over the long term. Sanofi or AbbVie comparison
• Negative Sentiment: One recent valuation analysis placed AbbVie’s estimated fair value below the market price, highlighting downside risk if the company’s pipeline or earnings growth fails to meet elevated expectations.
• Neutral Sentiment: An executive sale of AbbVie shares may attract some investor attention, although the available reports do not indicate that it reflects a change in the company’s fundamental outlook.

Insider Transactions at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.06% of the company’s stock.

Institutional Investors Weigh In On AbbVie

Large investors have recently added to or reduced their stakes in the company. State Street Corp grew its holdings in AbbVie by 1.7% in the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after purchasing an additional 1,379,232 shares during the last quarter. Corient Private Wealth LP purchased a new position in shares of AbbVie in the second quarter worth about $559,736,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of AbbVie by 0.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock valued at $3,590,323,000 after acquiring an additional 106,091 shares during the last quarter. Legal & General Group Plc acquired a new stake in shares of AbbVie in the second quarter worth $2,905,952,000. Finally, Deutsche Bank AG lifted its holdings in shares of AbbVie by 13.0% in the 2nd quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock valued at $2,710,905,000 after buying an additional 1,241,587 shares during the period. Institutional investors own 70.23% of the company’s stock.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.